Summary

Pneumonia Therapeutics Market – Scope of Report
TMR’s report on the global pneumonia therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global pneumonia therapeutics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pneumonia therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the pneumonia therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pneumonia therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pneumonia therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pneumonia therapeutics market.

The report delves into the competitive landscape of the global pneumonia therapeutics market. Key players operating in the global pneumonia therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pneumonia therapeutics market profiled in this report.

Key Questions Answered in Global pneumonia therapeutics Market Report
• What is the sales/revenue generated by pneumonia therapeutics across all regions during the forecast period?
• What are the opportunities in the global pneumonia therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Pneumonia Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global pneumonia therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pneumonia therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pneumonia therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Pneumonia Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pneumonia Therapeutics Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events
5.2. Regulatory Scenario
5.3. Disease Incidence & Prevalence Rate by Region/globally
5.4. COVID-19 Impact Analysis
6. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2017-2031
6.3.1. Bacterial Pneumonia
6.3.2. Viral Pneumonia
6.3.3. Fungal Pneumonia
6.4. Market Attractiveness By Type
7. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Age Group
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Age Group, 2017-2031
7.3.1. Children
7.3.2. Adult
7.3.3. Geriatric
7.4. Market Attractiveness By Age Group
8. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Route of Administration, 2017-2031
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Others
8.4. Market Attractiveness By Route of Administration
9. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Drug Class
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Drug Class, 2017-2031
9.3.1. Antibiotics
9.3.2. Antiviral Drugs
9.3.3. Antifungal Drugs
9.3.4. Corticosteroids
9.3.5. Others (NSAIDs, Cough suppressant, etc.)
9.4. Market Attractiveness By Drug Class
10. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Distribution Channel, 2017-2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness By Distribution Channel
11. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Region
11.1. Key Findings
11.2. Market Value Forecast By Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness By Country/Region
12. North America Pneumonia Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type, 2017-2031
12.2.1. Bacterial Pneumonia
12.2.2. Viral Pneumonia
12.2.3. Fungal Pneumonia
12.3. Market Value Forecast By Age Group, 2017-2031
12.3.1. Children
12.3.2. Adult
12.3.3. Geriatric
12.4. Market Value Forecast By Route of Administration, 2017-2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Others
12.5. Market Value Forecast By Drug Class, 2017-2031
12.5.1. Antibiotics
12.5.2. Antiviral Drugs
12.5.3. Antifungal Drugs
12.5.4. Corticosteroids
12.5.5. Others (NSAIDs, Cough suppressant, etc.)
12.6. Market Value Forecast By Distribution Channel, 2017-2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast By Country, 2017-2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Type
12.8.2. By Age Group
12.8.3. By Route of Administration
12.8.4. By Drug Class
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Pneumonia Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type, 2017-2031
13.2.1. Bacterial Pneumonia
13.2.2. Viral Pneumonia
13.2.3. Fungal Pneumonia
13.3. Market Value Forecast By Age Group, 2017-2031
13.3.1. Children
13.3.2. Adult
13.3.3. Geriatric
13.4. Market Value Forecast By Route of Administration, 2017-2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Others
13.5. Market Value Forecast By Drug Class, 2017-2031
13.5.1. Antibiotics
13.5.2. Antiviral Drugs
13.5.3. Antifungal Drugs
13.5.4. Corticosteroids
13.5.5. Others (NSAIDs, Cough suppressant, etc.)
13.6. Market Value Forecast By Distribution Channel, 2017-2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast By Country, 2017-2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Type
13.8.2. By Age Group
13.8.3. By Route of Administration
13.8.4. By Drug Class
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Pneumonia Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type, 2017-2031
14.2.1. Bacterial Pneumonia
14.2.2. Viral Pneumonia
14.2.3. Fungal Pneumonia
14.3. Market Value Forecast By Age Group, 2017-2031
14.3.1. Children
14.3.2. Adult
14.3.3. Geriatric
14.4. Market Value Forecast By Route of Administration, 2017-2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Others
14.5. Market Value Forecast By Drug Class, 2017-2031
14.5.1. Antibiotics
14.5.2. Antiviral Drugs
14.5.3. Antifungal Drugs
14.5.4. Corticosteroids
14.5.5. Others (NSAIDs, Cough suppressant, etc.)
14.6. Market Value Forecast By Distribution Channel, 2017-2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast By Country/Sub-region, 2017-2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of APAC
14.8. Market Attractiveness Analysis
14.8.1. By Type
14.8.2. By Age Group
14.8.3. By Route of Administration
14.8.4. By Drug Class
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Pneumonia Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Type, 2017-2031
15.2.1. Bacterial Pneumonia
15.2.2. Viral Pneumonia
15.2.3. Fungal Pneumonia
15.3. Market Value Forecast By Age Group, 2017-2031
15.3.1. Children
15.3.2. Adult
15.3.3. Geriatric
15.4. Market Value Forecast By Route of Administration, 2017-2031
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Others
15.5. Market Value Forecast By Drug Class, 2017-2031
15.5.1. Antibiotics
15.5.2. Antiviral Drugs
15.5.3. Antifungal Drugs
15.5.4. Corticosteroids
15.5.5. Others (NSAIDs, Cough suppressant, etc.)
15.6. Market Value Forecast By Distribution Channel, 2017-2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast By Country/Sub-region, 2017-2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of LATAM
15.8. Market Attractiveness Analysis
15.8.1. By Type
15.8.2. By Age Group
15.8.3. By Route of Administration
15.8.4. By Drug Class
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Pneumonia Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Type, 2017-2031
16.2.1. Bacterial Pneumonia
16.2.2. Viral Pneumonia
16.2.3. Fungal Pneumonia
16.3. Market Value Forecast By Age Group, 2017-2031
16.3.1. Children
16.3.2. Adult
16.3.3. Geriatric
16.4. Market Value Forecast By Route of Administration, 2017-2031
16.4.1. Oral
16.4.2. Parenteral
16.4.3. Others
16.5. Market Value Forecast By Drug Class, 2017-2031
16.5.1. Antibiotics
16.5.2. Antiviral Drugs
16.5.3. Antifungal Drugs
16.5.4. Corticosteroids
16.5.5. Others (NSAIDs, Cough suppressant, etc.)
16.6. Market Value Forecast By Distribution Channel, 2017-2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast By Country/Sub-region, 2017-2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of MEA
16.8. Market Attractiveness Analysis
16.8.1. By Type
16.8.2. By Age Group
16.8.3. By Route of Administration
16.8.4. By Drug Class
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2022)
17.3. Company Profiles
17.3.1. AstraZeneca
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. Novartis AG
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. AbbVie Inc.
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. Teva Pharmaceutical Industries Ltd.
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Sumitomo Pharma Co., Ltd.
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. Pfizer Inc.
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. Sanofi
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. Lupin Pharmaceuticals, Inc.
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Wockhardt Ltd.
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. Innoviva, Inc.
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments